
The primary purpose of fuel cell hybrid electric vehicles (FCHEVs) is to tackle the challenge of environmental pollution associated with road transport. However, to benefit from the enormous advantages presented by FCHEVs, an appropriate energy management system (EMS) is necessary for effective power distribution between the fuel cell and the energy storage systems (ESSs). The past decade has brought a significant increase in the number of FCHEVs, with different EMSs having been implemented due to technology advancement and government policies. These methods are broadly categorised into rule-based EMS methods, machine learning methods and optimisation-based control methods. Therefore, this paper presents a systematic literature review on the different EMSs and strategies used in FCHEVs, with special focus on fuel cell/lithium-ion battery hybrid electric vehicles. The contribution of this study is that it presents a quantitative evaluation of the different EMSs selected by comparing and categorising them according to principles, technology maturity, advantages and disadvantages. In addition, considering the drawbacks of some EMSs, gaps were highlighted for future research to create the pathway for comprehensive emerging solutions. Therefore, the results of this paper will be beneficial to researchers and electric vehicle designers saddled with the responsibility of implementing an efficient EMS for vehicular applications.
Citation: Samson Obu Showers, Atanda Kamoru Raji. State-of-the-art review of fuel cell hybrid electric vehicle energy management systems[J]. AIMS Energy, 2022, 10(3): 458-485. doi: 10.3934/energy.2022023
[1] | Kexin Li, Hu Chen, Shusen Xie . Error estimate of L1-ADI scheme for two-dimensional multi-term time fractional diffusion equation. Networks and Heterogeneous Media, 2023, 18(4): 1454-1470. doi: 10.3934/nhm.2023064 |
[2] | Panpan Xu, Yongbin Ge, Lin Zhang . High-order finite difference approximation of the Keller-Segel model with additional self- and cross-diffusion terms and a logistic source. Networks and Heterogeneous Media, 2023, 18(4): 1471-1492. doi: 10.3934/nhm.2023065 |
[3] | Zhe Pu, Maohua Ran, Hong Luo . Effective difference methods for solving the variable coefficient fourth-order fractional sub-diffusion equations. Networks and Heterogeneous Media, 2023, 18(1): 291-309. doi: 10.3934/nhm.2023011 |
[4] | Leqiang Zou, Yanzi Zhang . Efficient numerical schemes for variable-order mobile-immobile advection-dispersion equation. Networks and Heterogeneous Media, 2025, 20(2): 387-405. doi: 10.3934/nhm.2025018 |
[5] | Li-Bin Liu, Limin Ye, Xiaobing Bao, Yong Zhang . A second order numerical method for a Volterra integro-differential equation with a weakly singular kernel. Networks and Heterogeneous Media, 2024, 19(2): 740-752. doi: 10.3934/nhm.2024033 |
[6] | Xiongfa Mai, Ciwen Zhu, Libin Liu . An adaptive grid method for a singularly perturbed convection-diffusion equation with a discontinuous convection coefficient. Networks and Heterogeneous Media, 2023, 18(4): 1528-1538. doi: 10.3934/nhm.2023067 |
[7] | Yaxin Hou, Cao Wen, Yang Liu, Hong Li . A two-grid ADI finite element approximation for a nonlinear distributed-order fractional sub-diffusion equation. Networks and Heterogeneous Media, 2023, 18(2): 855-876. doi: 10.3934/nhm.2023037 |
[8] | Junjie Wang, Yaping Zhang, Liangliang Zhai . Structure-preserving scheme for one dimension and two dimension fractional KGS equations. Networks and Heterogeneous Media, 2023, 18(1): 463-493. doi: 10.3934/nhm.2023019 |
[9] | Fengli Yin, Dongliang Xu, Wenjie Yang . High-order schemes for the fractional coupled nonlinear Schrödinger equation. Networks and Heterogeneous Media, 2023, 18(4): 1434-1453. doi: 10.3934/nhm.2023063 |
[10] | Diandian Huang, Xin Huang, Tingting Qin, Yongtao Zhou . A transformed L1 Legendre-Galerkin spectral method for time fractional Fokker-Planck equations. Networks and Heterogeneous Media, 2023, 18(2): 799-812. doi: 10.3934/nhm.2023034 |
The primary purpose of fuel cell hybrid electric vehicles (FCHEVs) is to tackle the challenge of environmental pollution associated with road transport. However, to benefit from the enormous advantages presented by FCHEVs, an appropriate energy management system (EMS) is necessary for effective power distribution between the fuel cell and the energy storage systems (ESSs). The past decade has brought a significant increase in the number of FCHEVs, with different EMSs having been implemented due to technology advancement and government policies. These methods are broadly categorised into rule-based EMS methods, machine learning methods and optimisation-based control methods. Therefore, this paper presents a systematic literature review on the different EMSs and strategies used in FCHEVs, with special focus on fuel cell/lithium-ion battery hybrid electric vehicles. The contribution of this study is that it presents a quantitative evaluation of the different EMSs selected by comparing and categorising them according to principles, technology maturity, advantages and disadvantages. In addition, considering the drawbacks of some EMSs, gaps were highlighted for future research to create the pathway for comprehensive emerging solutions. Therefore, the results of this paper will be beneficial to researchers and electric vehicle designers saddled with the responsibility of implementing an efficient EMS for vehicular applications.
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 in Wuhan, China [1]. The COVID-19 pandemic has brought with over 528 million cases and more than 6.29 million confirmed deaths, overwhelming the healthcare system worldwide [2]. As the pandemic progresses, virus variants have showed up unabatedly. The B.1.617.2 (Delta) variant has a higher transmissibility and a stronger immune evasion capacity than B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) variants [3], and its high infectivity is associated with a high viral load and a short incubation period [4]. The Delta variant shows many mutations in the spike protein, which can bind to the angiotensin converting enzyme 2 (ACE2) receptor, thus contributing to the fusion and integration of the virus with the host cell [5]. As one of the two currently circulating variants of concern (VOCs) [6], the public health threat posed by Delta variant around the world cannot be underestimated.
Viral clearance in a COVID-19 patient is defined as two consecutive negative (polymerase chain reaction) PCR results with an interval of at least 24 hours [7]. A longer viral shedding indicates a worse prognosis of COVID-19 patients [8]. Some studies observed a significant increase in antibodies against spike protein after vaccination and a positive correlation with the level of 50% neutralizing titer [9,10]. There was a remarkably strong non-linear relationship between the mean neutralization level and the protective effect of vaccines [11]. Vaccines are effective to reduce the odds of hospitalization and severe disease due to the Delta variant [4]. Some studies adapted a cohort design to investigate the relationship between disease severity and viral shedding, found that the more severe the disease, the longer the viral shedding time [12,13,14]. A retrospective study with 410 COVID-19 patients showed that coronary heart disease (CHD), albumin level, and time of initial antiviral treatment all impacted viral shedding time [15]. Another retrospective cohort study found that delayed admission to hospital after illness onset and male sex were associated with prolonged SARS-CoV-2 RNA shedding [16]. Also, an observational, retrospective, single-centre study found that viral clearance was negatively with respiratory disease severity, comorbidities and delayed hospital admission [17]. Besides, a prospective study observed prolonged viral shedding in older, female and those with longer interval from symptom onset to admission [18].
Gong et al. [19] performed a simple correlation analysis of viral shedding and antibody level under a retrospective cohort of 564 participants, but found that viral shedding duration was not significantly correlated with antibody concentration. However, in this correlation analysis, the dynamic change of antibody level was not considered for exploring its influence on the duration of virus shedding. Significantly reduced duration of infectious viral shedding has been found among vaccinated individuals compared with unvaccinated individuals with a difference test [20]. But it failed to fully exploit longitudinal data on individual antibody levels to dynamically predict the timing of viral shedding in individuals. The joint model (JM) is a popular tool to process time-depending variables [21], which combines the mixed model or random effect model into the Cox model to construct the relationship between longitudinal covariates and the duration of an event [22]. Therefore, we monitored the dynamic change in antibody levels of hospitalized patients, and quantitatively analyzed its influence on the duration of viral shedding by using the JM model.
In this study we analyzed the effect of the vaccine on the patient's antibody levels at first admission using correlation analysis, then explored the relationships between prolonged viral shedding and the antibody level in patients infected with COVID-19 using JM based on repeated measurement indicators. Our findings could provide some theoretical support for the effectiveness and application of vaccines.
From July to August, 2021, we recruited a group of patients diagnosed with COVID-19 caused by SARS-CoV-2 B.1.617.2 (Delta) variant in Nanjing Second Hospital, the designated hospital for COVID-19 treatment in Jiangsu Province of China. The clinical classification was based on the "New Coronavirus Pneumonia Prevention and Control Program (Eighth Edition)". Enrollment criteria for this study were as follows: a. positive RT-PCR test for COVID-19 at admission; b. disappearance of symptoms after standardized treatment in the hospital; c. age ≥ 18 years old. This study was approved by the ethics committee of the Second Hospital of Nanjing (reference number: 2020-LS-ky003). Due to the anonymous processing of all patient private information in the article, the informed consent was waived with the approval of the Ethics Committee of Nanjing Medical University. Demographics, clinical and laboratory parameters, treatment management and outcome data were derived from the patients' medical history.
Initially, 544 patients were recruited, and 27 patients aged < 18 years old were excluded. According to the definition of viral shedding, 143 patients lacking nucleic acid test information within 48 hours were also excluded. In further analysis, 13 patients with outliers were excluded (Figure 1). Finally, 361 patients were included.
The joint model is constructed to infer the dependence and degree of correlation between longitudinal data and survival data, thus enabling a better assessment of the effectiveness of a decision or treatment measure [22,23]. The joint model has two basic components: the longitudinal submodel and the survival submodel.
In this study, we assumed a generalized linear mixed-effects model with the following structure:
g[E{yi(t)∣bi}]=ηi(t)=xTi(t)β+zTi(t)bi | (1) |
where g(⋅) denoted a known one-to-one monotonic link function, yi(t) denoted the value of the ith subject at time point t, ηi(t) denoted the true level of potential longitudinal measurement values at time t and xi(t) and zi(t) denoted the design vectors for the fixed effects β and the random effects bi. bi was assumed to follow a multivariate normal distribution with mean zero and variance-covariance matrix D. For the survival submodel, we assumed that the risk of an event at moment t depended on an individual-specific linear predictor function ηi(t). Specifically, we had
hi(t∣Hi(t),ωi(t))=limΔt→0 Pr{t≤T∗i<t+Δt∣T∗i≥t,Hi(t),ωi(t)}Δt,t>0=h0(t)exp[γ⊤ωi(t)+f{Hi(t),bi,α}], | (2) |
where Hi(t)={ηi(s),0≤s≤t} denoted the history of the underlying longitudinal process up to t for subject i. h0(⋅) denoted the baseline hazard function and ωi(t) was covariates (exogenous, possibly time-varying) with corresponding regression coefficients γ.
f{Hi(t),bi,α}=αηi(t), | (3) |
where Hi(t)={ηi(s),0≤s≤t} denoted the true observed longitudinal process trajectory up to time point t for subject i, and h0(⋅) denoted the baseline hazard function. ωi(t) was a vector of covariates, and γ was the regression coefficient. The longitudinal and survival submodels were connected by the parameter α, which quantified the effect of potential longitudinal outcomes on event risk. The baseline hazard function h0(⋅) was usually not specified in the standard Cox model, but h0(⋅) needed to be explicitly defined in the joint model. The baseline hazard function h0(⋅) was flexibly modeled using a B-splines approach,
logh0(t)=γh0,0+∑Qq=1 γh0,qBq(t,v), | (4) |
Bq(t,v) denoted the qth basis function 1, …, vQ and γh0 spline coefficient vector of the B-splines with v as the node, usually Q = 15 or 20.
The Bayesian approach was used to develop a joint model for longitudinal and survival data, and the estimation method followed the Markov chain Monte Carlo (MCMC) algorithm. The JMbayes package in R was implemented. The theoretical development of the posterior distribution was based on the assumption that both longitudinal and survival processes were independent under the influence of a given random effect. In addition, the longitudinal response needed to consider the general assumption of independence of random effects. If θ denoted the set of all fixed parameters and b denoted the set of random parameters, , it was possible to determine the probability density function p(⋅) as
p(yi,Ti,δi∣bi,θ)=p(yi∣bi,θ)p(Ti,δi∣bi,θ), | (5) |
and
p(yi∣bi,θ)=∏l p(yil∣bi,θ), | (6) |
Under these assumptions, the posterior distribution was similar to
p(θ,b)∝∏ni=0 ∏nil=1 p(yil∣bi,θ)p(Ti,δi∣bi,θ)p(bi∣θ)p(θ). | (7) |
After data processing, 361 patients were included. The outliers and null values were imputed, the most frequent values were used to impute categorical variables, while the mean values were used to express continuous variables. Based on the fact that the duration of viral shedding was generally 2 or 3 weeks in different variants, and the median time of viral shedding in this study is 25 days, we chose 3 weeks as the time point of the viral shedding group. We divided the patients into two groups according to the duration of viral shedding (≤ 21 days group and > 21 days group). Patients' characteristics were compared between the two groups, categorical variables were expressed as frequency (%), and continuous variables were expressed as medians (with interquartile range [IQR]). The statistically significant level was set at 0.05 (Table 1). No obvious difference was found in the median age between the two groups (49 years vs. 50 years, p = 0.101). Female patients accounted for a higher proportion than males. Among all patients, 104 (28.8%) suffered basic diseases (such as hypertension, diabetes, heart attack, and tumor), and the rate of basic diseases showed no difference between the two groups (p = 0.706). Totally, 240 patients (66.5%) received vaccination, and the impact of vaccination on the duration of viral shedding was obvious (p = 0.046). The median time from illness onset to hospitalization was about 2 days. The main symptoms were fever, cough, sputum production and shortness of breath. The blood laboratory indicators included C-reactive protein (mg/L), procalcitonin (ng/mL), interleukin-6 (pg/mL), white blood cell count (109/L), neutrophil count (109/L), lymphocyte count (109/L), hemoglobin(g/L), platelet count(109/L), albumin(g/L), total bilirubin (umol/L), AST (U/L), ALT (U/L), urea nitrogen (mmol/L), creatinine (mol/L), eGFR (ml/min), creatine kinase (U/L), CK-MB (ng/mL), myoglobin (ng/mL), troponin I (pg/mL), LDH (U/L), prothrombin time (s), D-dimer (mg/L), and FDPs (ug/mL) (Table1). Two types of antibodies, SARS-COV-2 IgM sample/cutoff (S/CO) and SARS-COV-2 IgG (S/CO), were included in this study and the patient's antibody level at admission showed obvious difference between the two groups. Bar plot of the number of new admissions stratified by vaccination status was drawn (Figure 2). Since 20 July, the number of cases admitted to hospital has fluctuated. The peak was between August 2 and August 4, and the proportion of unvaccinated people on these three days was relatively high.
Overall (n =361) | Duration of viral shedding ≤ 21d (n =111) |
Duration of viral shedding > 21d (n =250) |
P-value |
||
Demographics and clinical characteristics | |||||
Sex | |||||
Male | 139 (38.5) | 47 (42.3) | 92 (36.8) | 0.349 | |
Female | 222 (61.5) | 64 (57.7) | 158 (63.2) | ||
Age, years | 50.00 [40.00, 65.00] | 49.00 [34.50, 62.00] | 50.00 [41.00, 66.00] | 0.101 | |
With any comorbidity | |||||
No | 257 (71.2) | 81 (73.0) | 176 (70.4) | 0.706 | |
Yes | 104 (28.8) | 30 (27.0) | 74 (29.6) | ||
Hypertension | |||||
No | 284 (78.7) | 90 (81.1) | 194 (77.6) | 0.489 | |
Yes | 77 (21.3) | 21 (18.9) | 56 (22.4) | ||
Diabetes | |||||
No | 330 (91.4) | 105 (94.6) | 225 (90.0) | 0.221 | |
Yes | 31 (8.6) | 6 (5.4) | 25 (10.0) | ||
Heart disease | |||||
No | 349 (96.7) | 106 (95.5) | 243 (97.2) | 0.525 | |
Yes | 12 (3.3) | 5 (4.5) | 7 (2.8) | ||
COPD | |||||
No | 361 (100.0) | 111 (100.0) | 250 (100.0) | ||
Yes | 0(0.0) | 0(0.0) | 0(0.0) | ||
Carcinoma history | |||||
No | 353 (97.8) | 111 (100.0) | 242 (96.8) | 0.113 | |
Yes | 8 (2.2) | 0 (0.0) | 8 (3.2) | ||
Asthma | |||||
No | 356 (98.6) | 111 (100.0) | 245 (98.0) | 0.329 | |
Yes | 5 (1.4) | 0 (0.0) | 5 (2.0) | ||
Autoimmune diseases | |||||
No | 357 (98.9) | 110 (99.1) | 247 (98.8) | 1.000 | |
Yes | 4 (1.1) | 1 (0.9) | 3 (1.2) | ||
Vaccination Status | |||||
Unvaccinated | 121 (33.5) | 29 (26.1) | 92 (36.8) | 0.046 | |
Partially vaccinated | 64 (17.7) | 17 (15.3) | 47 (18.8) | ||
Fully vaccinated | 176 (48.8) | 65 (58.6) | 111 (44.4) | ||
Time from illness onset to hospitalization (median [IQR]) | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 0.192 | |
Symptoms | |||||
Fever | |||||
No | 247 (68.4) | 77 (69.4) | 170 (68.0) | 0.902 | |
Yes | 114 (31.6) | 34 (30.6) | 80 (32.0) | ||
Cough | |||||
No | 179 (49.6) | 56 (50.5) | 123 (49.2) | 0.909 | |
Yes | 182 (50.4) | 55 (49.5) | 127 (50.8) | ||
Sputum production | |||||
No | 294 (81.4) | 90 (81.1) | 204 (81.6) | 0.885 | |
Yes | 67 (18.6) | 21 (18.9) | 46 (18.4) | ||
Shortness of breath | |||||
No | 349 (96.7) | 109 (98.2) | 240 (96.0) | 0.357 | |
Yes | 12 (3.3) | 2 (1.8) | 10 (4.0) | ||
Nausea or vomiting | |||||
No | 355 (98.3) | 110 (99.1) | 245 (98.0) | 0.671 | |
Yes | 6 (1.7) | 1 (0.9) | 5 (2.0) | ||
Abdominal pain or diarrhea | |||||
No | 340 (94.2) | 103 (92.8) | 237 (94.8) | 0.470 | |
Yes | 21 (5.8) | 8 (7.2) | 13 (5.2) | ||
Loss of smell or taste | |||||
No | 347 (96.1) | 105 (94.6) | 242 (96.8) | 0.377 | |
Yes | 14 (3.9) | 6 (5.4) | 8 (3.2) | ||
Myalgia | |||||
No | 351 (97.2) | 108 (97.3) | 243 (97.2) | 1.000 | |
Yes | 10 (2.8) | 3 (2.7) | 7 (2.8) | ||
Stuffy nose or runny nose | |||||
No | 311 (86.1) | 92 (82.9) | 219 (87.6) | 0.249 | |
Yes | 50 (13.9) | 19 (17.1) | 31 (12.4) | ||
Headache or dizziness | |||||
No | 334 (92.5) | 106 (95.5) | 228 (91.2) | 0.195 | |
Yes | 27 (7.5) | 5 (4.5) | 22 (8.8) | ||
Fatigue | |||||
No | 291 (80.6) | 93 (83.8) | 198 (79.2) | 0.387 | |
Yes | 70 (19.4) | 18 (16.2) | 52 (20.8) | ||
Pharyngeal discomfort | |||||
No | 280 (77.6) | 91 (82.0) | 189 (75.6) | 0.219 | |
Yes | 81 (22.4) | 20 (18.0) | 61 (24.4) | ||
Blood laboratory findings | |||||
C-reactive protein, mg/L | 5.41 [2.04, 14.31] | 5.77 [1.31, 17.01] | 5.21 [2.52, 13.53] | 0.868 | |
Procalcitonin, ng/mL | 0.04 [0.02, 0.06] | 0.04 [0.02, 0.07] | 0.04 [0.03, 0.06] | 0.583 | |
Interleukin-6, pg/mL | 10.06 [2.81, 21.13] | 10.69 [4.54, 21.02] | 9.80 [2.33, 20.95] | 0.453 | |
White blood cell count, × 109/L | 4.82 [3.91, 5.98] | 4.79 [3.84, 6.30] | 4.85 [3.94, 5.90] | 0.918 | |
Neutrophil count, × 109/L | 3.00 [2.19, 4.02] | 2.94 [2.06, 4.19] | 3.04 [2.28, 3.86] | 0.679 | |
Lymphocyte count, × 109/L | 1.15 [0.88, 1.54] | 1.23 [1.00, 1.60] | 1.11 [0.86, 1.47] | 0.017 | |
Hemoglobin, g/dL | 13.20 [12.30, 14.60] | 13.40 [12.35, 14.85] | 13.10 [12.30, 14.50] | 0.352 | |
Platelet count, × 109/L | 157.00 [121.00,192.00] | 165.00 [130.00,200.50] | 152.00 [118.25,189.00] | 0.102 | |
Albumin, g/L | 42.80 [40.40, 45.30] | 43.10 [40.60, 45.45] | 42.70 [40.20, 45.20] | 0.261 | |
Total bilirubin, umol/L | 9.70 [7.60, 12.30] | 9.90 [7.75, 12.10] | 9.50 [7.53, 12.57] | 0.981 | |
AST, U/L | 17.00 [13.90, 23.10] | 16.10 [13.65, 23.30] | 17.30 [14.35, 23.10] | 0.189 | |
ALT, U/L | 18.10 [12.20, 28.50] | 19.50 [12.00, 30.80] | 17.40 [12.35, 28.10] | 0.702 | |
Urea nitrogen, mmol/L | 4.36 [3.59, 5.24] | 4.33 [3.62, 5.22] | 4.40 [3.59, 5.27] | 0.615 | |
Creatinine, μmol/L | 60.80 [51.90, 74.90] | 63.50 [54.80, 76.50] | 59.15 [51.12, 74.12] | 0.045 | |
eGFR, mL/min | 111.95 [105.75,117.14] | 111.95 [104.68,119.67] | 111.95 [106.93,115.50] | 0.944 | |
Creatine kinase, U/L | 71.00 [50.00,112.00] | 71.00 [51.50,104.00] | 69.50 [50.00,115.75] | 0.698 | |
CK-MB, ng/mL | 0.50 [0.30, 0.80] | 0.50 [0.30, 0.85] | 0.50 [0.30, 0.80] | 0.990 | |
Myoglobin, ng/mL | 34.05 [23.60, 49.50] | 34.05 [25.80, 49.90] | 34.05 [22.22, 48.98] | 0.464 | |
Troponin I, pg/mL | 3.00 [1.00, 6.20] | 3.00 [0.80, 5.45] | 3.00 [1.10, 6.40] | 0.580 | |
LDH, U/L | 237.00 [202.00,280.00] | 234.00 [200.00,269.50] | 238.50 [206.00,284.00] | 0.251 | |
D-dimer, mg/L | 0.39 [0.25, 0.60] | 0.40 [0.25, 0.67] | 0.38 [0.25, 0.60] | 0.957 | |
FDPs, ug/mL | 2.70 [1.70, 5.10] | 3.10 [1.55, 5.40] | 2.70 [1.70, 4.10] | 0.242 | |
SARS-COV-2 IgM (S/CO) | 0.19 [0.06, 0.75] | 0.34 [0.11, 1.36] | 0.15 [0.05, 0.60] | < 0.001 | |
SARS-COV-2 IgG (S/CO) | 1.13 [0.15, 7.61] | 3.31 [0.38, 25.44] | 0.67 [0.11, 3.95] | < 0.001 | |
Abbreviations: AST, Aspartate Transaminase; ALT, Alanine Aminotransferase; eGFR, estimated Giomerular Filtration Rate; CK-MB, Creatine Kinase Isoenzyme; LDH, Lactic Dehydrogenase; FDPs, Fibrinogen Degrdtion Products; SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
The median interval between a patient's last vaccination and the first sampling was 47 days. We found that the patients having received vaccination had a higher antibody level at admission than unvaccinated patients, and the overall median of SARS-COV-2 IgM and SARS-COV-2 IgG were 0.19 and 1.13, respectively (Figure 3). The median levels of SARS-COV-2 IgM and SARS-COV-2 IgG in unvaccinated patients were 0.05 and 0.10, respectively; while in fully vaccinated patients, the median levels were 0.30 and 4.77, respectively (Table 2). Furthermore, we drew the scatter plot of the relationship between the antibody level and duration of viral shedding (Figure 3 (C), (D)) and found that with the increase of antibody concentration, the duration of viral shedding turned shorter. To explore how the dynamic antibody concentration influenced the patient's prolonged viral shedding duration, we made further analysis using the JM with repeated measurement antibody data.
Vaccination status | |||||
Type of antibody | Overall | fully vaccinated | partially vaccinated | unvaccinated | |
SARS-COV-2 IgM (median [IQR]) |
0.19 [0.06, 0.75] | 0.30 [0.10, 1.17] | 0.36 [0.08, 0.96] | 0.05 [0.03, 0.31] | |
SARS-COV-2 IgG (median [IQR]) | 1.13 [0.15, 7.61] | 4.77 [2.24, 24.41] | 0.43 [0.15, 1.62] | 0.10 [0.05, 0.25] | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
Figure 4 provides sample subject-specific longitudinal traces for log SARS-COV-2 IgM (S/CO) in patients with and without endpoints. The figure clearly depicts the complexity of the data and the flatter SARS-COV-2 IgM (S/CO) levels in patients with 21-day viral shedding. The fitted model takes into account the relevant random intercept and slope of the model. The results of the linear mixed-effects model showed the longitudinal variation of logSARS-COV-2 IgM (S/CO) values, with a parameter estimate of 0.193 and a standard error of 0.017 (Table 3). A significant increasing trend was observed in Log (SARS-COV-2 IgM (S/CO)) over time. Then, a Cox model was fitted, with gender as an interdependent variable, and the risk function of viral shedding (or not) within 21 days was modeled as the outcome variable. The parameter estimates of the model and their standard errors are given in Table 4. Figure 5 shows the Kaplan-Meier of the probability of survival of viral shedding between the different genders. Finally, the joint model output showed that SARS-COV-2 IgM (S/CO) level was strongly associated with the risk of a composite event at the 95% confidence level (Table 5). A doubling of SARS-COV-2 IgM (S/CO) level was associated with a 1.38-fold1 (95% CI: [1.16, 1.72]) increase in the risk of viral non-shedding.
1 The difference on the logarithmic scale of IgM is 0.693, which corresponds to a ratio of 2 on the original scale, so exp(0.693 Assoct) gives the corresponding hazard ratio for doubling of IgM.
Effects | Parameter | Estimate | Std Err | P value |
Log(SARS-COV-2) IgM (S/CO)) | Intercept | -1.405 | 0.082 | < 0.001 |
days | 0.193 | 0.017 | < 0.001 | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M |
Parameter | Estimate | exp(coef) | Std Err | P value |
Sex | 0.205 | 1.228 | 0.1093 | 0.0608 |
Parameter | Estimate | Std Err | P value |
Sex | 0.274 | 0.005 | 0.056 |
Assoct | 0.430 | 0.039 | < 0.001 |
Based on the joint model, we made dynamic prediction about the survival outcome of a randomly selected individual. More formally, based on the joint model, we were interested in deriving a probability prediction of viral shedding in a subject who provided a set of longitudinal measurements. With the help of the survivfitJM () and predict () functions in the JMbayes package, we dynamically predicted the time to viral shedding in Patient 361 based on the values of longitudinal changes in SARS-COV-2 IgM (S/CO) antibody level (Figure 6).
We observed that Patient 361 had a low baseline SARS-COV-2 IgM (S/CO) antibody level at admission and her probability of no shedding virus within 21 days was high. But her longitudinal profile showed a sharp increase in IgM antibody level, and accordingly, her probability of shedding virus within 21 days increased.
In this study, we established a joint model, which took full advantage of repeated measurements, to explore the factors contributing to the prolonged viral shedding. We found little connection between the duration of viral shedding and some basic variables varying with time, such as routine blood indicators, though they had been measured at many time points with slight fluctuation. Through correlation analysis, patients having received vaccination were found to have higher antibody levels, and at the same time, baseline information showed that prolonged viral shedding was related to a low antibody level. Using the linear mixed-effects model, we found that the concentration of SASRS-COV-2 IgM (S/CO) varied with time obviously. Through the Cox proportional hazards model, difference was found in the length of viral shedding between the two genders. By combining the results of the linear mixed-effects model into the Cox model, the joint model output showed that SARS-COV-2 IgM (S/CO) level was strongly associated with the risk of a composite event at the 95% confidence level, with a doubling of SARS-COV-2 IgM (S/CO) level and an increased risk of 1.38-fold (95% CI: [1.16, 1.72]). A study has found that COVID-19 patients with positive anti-SARS-CoV-2 IgM results have a short duration of viral shedding [24], which is consistent with the finding in this study. Our study is the first to investigate the correlation between SARS-COV-2 IgM (S/CO) and Delta variant-infected patients using datasets with repeated measurements and time-to-event outcomes.
SARS-CoV-2 spike binds to its receptor ACE2 through its receptor-binding domain (RBD) to enter human cells [25]. High levels of IgM, and IgG anti-SARS-CoV-2 spike protein and RBD binding titer were found in volunteers after the second vaccine injection [26]. Besides, IgM plays a pivotal role in both humoral and mucosal immunity and it is a mucosal antibody that constitutes the first line of defense against mucosal pathogens [27]. Moreover, IgM antibodies that contain neutralizing antibodies directed against different epitopes of the Spike glycoprotein [28,29]. When infected by SARS-CoV-2, neutralizing antibodies recognize multiple regions within the spike glycoprotein, primarily in but not limited to the RBD, and inhibit viral infectivity through multiple mechanisms, including blocking the initial spike binding to ACE2 [29,30]. Ku et al. [31] engineered an IgM neutralizing antibody, which offered broad protection from SARS-CoV-2 variants. Vaccines can reduce the COVID-19-related hospitalization and death, as well as the asymptomatic SARS-CoV-2 infection [32]. A study has showed that infections occurring 12 days or longer after vaccination can significantly reduce viral loads, potentially affecting viral shedding and contagiousness [33]. Also, Chia et al. 9 have found a faster decrease of viral load and stronger boosting of anti-spike antibodies in vaccinated patients with Delta variants compared to those unvaccinated.
There are some advantages in this research. We made full use of the patients' longitudinal dada, adding to the credibility of the results. Using the joint model we established, the dynamic prediction was made about the survival outcome of a given individual, providing more accurate anticipations to health workers. Also, we confirmed that patients having been vaccinated had a higher antibody level, thus accelerating viral shedding. However, there are some limitations in our study: We failed to find the impact of SARS-CoV-2 IgG on viral shedding, which might be attributed to insufficient sample size. And we guess that the longitudinal data of IgG may exert impacts on severe patients, which needs further study. Moreover, with the emergence of the new variant of COVID-19, the Omicron variant has spread widely in China, but this study on the relationship between antibodies and viral shedding can still provide certain methods and ideas for similar research on different variants in the future.
By making full use of the patients' longitudinal records, we established the joint model, suggesting that higher antibody level in vaccinated patients, along with the presence of high-level SARS-COV-2 IgM antibodies in the serum, can accelerate viral shedding. This model can maximize the use of individual repeated data, explore the influencing factors of virus shedding, and provide certain ideas for relevant personnel to formulate prevention and treatment strategies for SARS-CoV-2.
This work was supported by the Natural Science Foundation of China (82073673, 11961071), the National S & T Major Project Foundation of China (2018ZX10715002-004-002), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Natural Science Foundation of Xinjiang (Grant Nos.2021D01C268), and Youth science and technology innovation talent of Tianshan Talent Training Program in Xinjiang (2022TSYCCX0099).
All authors declare no conflicts of interest in this paper.
[1] | Fletcher T (2017) Optimal energy management strategy for a fuel cell hybrid electric vehicle. Loughborough University. Available from: https://hdl.handle.net/2134/25567. |
[2] | Erensoy SC (2018) Simulation and energy management strategy development for a fuel cell hybrid electric powertrain of a zero-emission boat. Tecnico Lisboa. Available from: https://fenix.tecnico.ulisboa.pt/downloadFile/563345090416864. |
[3] | Bendjedia B, Alloui H, Rizoug N, et al. (2016) Sizing and energy management strategy for hybrid FC/Battery electric vehicle. IECON Proceedings (Industrial Electronics Conference), Florence, Italy, IEEE, 2111-2116. https://doi.org/10.1109/IECON.2016.7793271 |
[4] |
Sorlei I-S, Bizon N, Thounthong P, et al. (2021) Fuel cell electric vehicles—A brief review of current topologies and energy management strategies. Energies 14: 2-27. https://doi.org/10.3390/en14010252 doi: 10.3390/en14010252
![]() |
[5] | Carnevali MLS (2017) Modelling and control of PEM fuel cells. Universitat Politecnica de Catalunya. Available from: https://mat-web.upc.edu/people/carles.batlle/fitxers/thesis_MLSC.pdf. |
[6] |
Sulaiman N, Hannan MA, Mohamed A, et al. (2018) Optimization of energy management system for fuel-cell hybrid electric vehicles: Issues and recommendations. Appl Energy 228: 2061-2079. https://doi.org/10.1016/j.apenergy.2018.07.087 doi: 10.1016/j.apenergy.2018.07.087
![]() |
[7] |
Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339: 332-336. https://doi.org/10.1136/bmj.b2535 doi: 10.1136/bmj.b2535
![]() |
[8] |
Sulaiman N, Hannan MA, Mohamed A, et al. (2015) A review on energy management system for fuel cell hybrid electric vehicle: Issues and challenges. Renewable Sustainable Energy Rev 52: 802-814. http://dx.doi.org/10.1016/j.rser.2015.07.132 doi: 10.1016/j.rser.2015.07.132
![]() |
[9] | Fonseca RN da (2013) Optimization of the sizing and energy management strategy for a hybrid fuel cell vehicle including fuel cell dynamics and durability constraints. Institut National des Sciences Appliquées de Lyon-INSA Lyon. Available from: http://theses.insa-lyon.fr/publication/2013ISAL0110/these.pdf. |
[10] | Mokrani Z, Rekioua D, Mebarki N, et al. (2016) Energy management of Battery-PEM fuel cells hybrid energy storage system for electric vehicles. International Renewable and Sustainable Energy Conference (IRSEC), 1-70. https://doi.org/10.1109/IRSEC.2016.7984073 |
[11] |
Odeim F, Roes J, Heinzel A (2015) Power management optimization of an experimental Fuel Cell/Battery/Supercapacitor hybrid system. Energies 8: 6302-6327. https://doi.org/10.3390/en8076302 doi: 10.3390/en8076302
![]() |
[12] |
Alloui H, Achour Y, Marouani K, et al. (2015) Energy management based on frequency decoupling: Experimental results with fuel cell-electric vehicle emulator. IEEE Veh Technol Conf 2015: 1-5. https://doi.org/10.1109/VTCSpring.2015.7145811 doi: 10.1109/VTCSpring.2015.7145811
![]() |
[13] |
Ates Y, Erdinc O, Uzunoglu M, et al. (2010) Energy management of an FC/UC hybrid vehicular power system using a combined neural network-wavelet transform based strategy. Int J Hydrogen Energy 35: 774-783. https://doi.org/10.1016/j.ijhydene.2009.11.021 doi: 10.1016/j.ijhydene.2009.11.021
![]() |
[14] | Rousseau A, Sharer P, Ahluwalia R (2004) Energy storage requirements for fuel cell vehicles. 1-12. https://doi.org/10.4271/2004-01-1302 |
[15] | Vaz WS (2015) Energy management in electric vehicles: Development and validation of an optimal driving strategy. Missouri University of Science and Technology. Available from: https://scholarsmine.mst.edu/doctoral_dissertations/2422. |
[16] |
Tran DD, Vafaeipour M, El Baghdadi M, et al. (2020) Thorough State-of-the-Art analysis of electric and hybrid vehicle powertrains: Topologies and integrated energy management strategies. Renewable Sustainable Energy Rev 119: 2-30. https://doi.org/10.1016/j.rser.2019.109596 doi: 10.1016/j.rser.2019.109596
![]() |
[17] |
Yang C, Zha M, Wang W, et al. (2020) Efficient energy management strategy for hybrid electric vehicles/plug-in hybrid electric vehicles: Review and recent advances under intelligent transportation system. IET Intell Transp Syst 14: 702-711. https://doi.org/10.1049/iet-its.2019.0606 doi: 10.1049/iet-its.2019.0606
![]() |
[18] |
Zhang F, Hu X, Langari R, et al. (2019) Energy management strategies of connected HEVs and PHEVs: Recent progress and outlook. Prog Energy Combust Sci 73: 235-256. https://doi.org/10.1016/j.pecs.2019.04.002 doi: 10.1016/j.pecs.2019.04.002
![]() |
[19] |
Zhang Q, Li G (2019) A game theory energy management strategy for a fuel cell/battery hybrid energy storage system. Math Probl Eng 2019: 1-12. https://doi.org/10.1155/2019/7860214 doi: 10.1155/2019/7860214
![]() |
[20] |
Hu Y, Li W, Xu K, et al. (2018) Energy management strategy for a hybrid electric vehicle based on deep reinforcement learning. Appl Sci 8: 1-15. https://doi.org/10.3390/app8020187 doi: 10.3390/app8020187
![]() |
[21] |
Hu J, Jiang X, Jia M, et al. (2018) Energy management strategy for the hybrid energy storage system of pure electric vehicle considering traffic information. Appl Sci 8: 2-16. https://doi.org/10.3390/app8081266 doi: 10.3390/app8081266
![]() |
[22] | Panchal S (2014) Impact of vehicle charge and discharge cycles on the thermal characteristics of lithium-ion batteries. University of Waterloo. Available from: http://hdl.handle.net/10012/8423. |
[23] |
Li P, Yan J, Tu Q, et al. (2018) A novel energy management strategy for series hybrid electric rescue vehicle. Math Probl Eng 2018: 1-14. https://doi.org/10.1155/2018/8450213 doi: 10.1155/2018/8450213
![]() |
[24] | George SS (2018) A modular multi-level converter for energy management of hybrid storage system in electric vehicles. San Jose State University. https://doi.org/10.1109/ITEC.2018.8450237 |
[25] |
Song K, Li F, Hu X, et al. (2018) Multi-Mode energy management strategy for fuel cell electric vehicles based on driving pattern identification using learning vector quantization neural network algorithm. J Power Sources 389: 230-239. https://doi.org/10.1016/j.jpowsour.2018.04.024 doi: 10.1016/j.jpowsour.2018.04.024
![]() |
[26] | Hemi H, Ghouili J, Cheriti A (2013) A real time energy management for electrical vehicle using combination of rule-based and ECMS. IEEE Electrical Power and Energy Conference, EPEC, Halifax, Nova Scotia, Canada, IEEE, 2-7. https://doi.org/10.1109/EPEC.2013.6802927 |
[27] |
Li Q, Su B, Pu Y, et al. (2019) A state machine control based on equivalent consumption minimization for fuel cell/ supercapacitor hybrid tramway. IEEE Trans Transp Electrif 5: 552-564. https://doi.org/10.1109/TTE.2019.2915689 doi: 10.1109/TTE.2019.2915689
![]() |
[28] | Silva MA, De Melo HN, Trovao JP, et al. (2013) An integrated fuzzy logic energy management for a dual-source electric vehicle. IECON Proceedings (Industrial Electronics Conference), Vienna, Austria, IEEE, 4564-4569. https://doi.org/10.1109/IECON.2013.6699871 |
[29] |
Li CY, Liu GP (2009) Optimal fuzzy power control and management of fuel cell/battery hybrid vehicles. J Power Sources 192: 525-533. https://doi.org/10.1016/j.jpowsour.2009.03.007 doi: 10.1016/j.jpowsour.2009.03.007
![]() |
[30] | Ehsani M, Gao Y, Emadi A (2010) Modern Electric, Hybrid Electric, and Fuel Cell Vehicles, 3 Eds., New York: CRC Press, 421-470. https://doi.org/10.1201/9781420054002 |
[31] |
Saeks R, Cox CJ, Neidhoefer J, et al. (2002) Adaptive control of a hybrid electric vehicle. IEEE Trans Intell Transp Syst 3: 213-233. https://doi.org/10.1109/TITS.2002.804750 doi: 10.1109/TITS.2002.804750
![]() |
[32] | Mohebbi M, Charkhgard M, Farrokhi M (2005) Optimal neuro-fuzzy control of parallel hybrid electric vehicles. IEEE Vehicle Power and Propulsion Conference, VPPC, Chicago, USA, Researchgate, 252-256. https://doi.org/10.1109/VPPC.2005.1554566 |
[33] | Dazhi W, Jie Y, Qing Y, et al. (2007) Estimation and control of hybrid electric vehicle using artificial neural networks. IEEE Conference on Industrial Electronics and Applications, Harbin, China, 35-40. https://doi.org/10.1109/ICIEA.2007.4318365 |
[34] | Chen ZH, Masrur MA, Murphey YL (2008) Intelligent vehicle power management using machine learning and fuzzy logic. IEEE International Conference on Fuzzy Systems, Hong Kong, China., Researchgate, 2351-2358. https://doi.org/10.1109/FUZZY.2008.4630697 |
[35] | Hajimiri MH, Salmasi FR (2006) A fuzzy energy management strategy for series hybrid electric vehicle with predictive control and durability extension of the battery. IEEE Conference on Electric and Hybrid Vehicles, ICEHV, Pune, India, IEEE, 1-5. https://doi.org/10.1109/ICEHV.2006.352279 |
[36] | Gang S, Yuanwei J, Aidong X, et al. (2006) Study and simulation of based-fuzzy-logic parallel hybrid electric vehicles control strategy. International Conference on Intelligent Systems Design and Applications, Jinan, China, IEEE, Computer Society, 280-284. https://doi.org/10.1109/ISDA.2006.252 |
[37] |
Wu J, Zhang C, Cui N (2012) Combustion and emission characteristics of wood pyrolysis oil-butanol blended fuels in a di diesel engine. Int J Automot Technol 13: 1159-1167. https://doi.org/10.1007/s12239-015-0092-4 doi: 10.1007/s12239-015-0092-4
![]() |
[38] |
Poursamad A, Montazeri M (2008) Design of genetic-fuzzy control strategy for parallel hybrid electric vehicles. Control Eng Pract 16: 861-873. https://doi.org/10.1016/j.conengprac.2007.10.003 doi: 10.1016/j.conengprac.2007.10.003
![]() |
[39] | Böhme TJ, Benjamin F (2017) Hybrid systems, optimal control and hybrid vehicles. Cham, Switzerland, Springer Nature, 100-200. https://doi.org/10.1007/978-3-319-51317-1 |
[40] | Jeon B (2020) Energy management system in naval submarines. IEEE Transportation Electrification Conference & Expo (ITEC), 10-100. https://doi.org/10.1109/ITEC48692.2020.9161480 |
[41] | Herb F, Akula PR, Trivedi K, et al. (2013) Theoretical analysis of energy management strategies for fuel cell electric vehicle with respect to fuel cell and battery aging. World Electric Vehicle Symposium and Exhibition, EVS 27, Barcelona, Spain, EVS27, 1-9. https://doi.org/10.1109/EVS.2013.6915049 |
[42] |
Sun D, Lin X, Qin D, et al. (2012) Power-Balancing instantaneous optimization energy management for a novel series-parallel hybrid electric bus. Chinese J Mech Eng (English Ed) 25: 1161-1170. https://doi.org/10.3901/CJME.2012.06.1161 doi: 10.3901/CJME.2012.06.1161
![]() |
[43] | Tazelaar E, Veenhuizen B, Jagerman J, et al. (2013) Energy management strategies for fuel cell hybrid vehicles; an overview. International Battery, Hybrid and Fuel Cell Electric Vehicle Symposium, Barcelona, Spain, EVS27, 1-12. https://doi.org/10.1109/EVS.2013.6915039 |
[44] |
Schouten NJ, Salman MA, Kheir NA (2002) Fuzzy logic control for parallel hybrid vehicles. IEEE Trans Control Syst Technol 10: 460-468. https://doi.org/10.1109/87.998036 doi: 10.1109/87.998036
![]() |
[45] | Salmanx M, Schouten NJ, Naim AK (2000) Control strategies for parallel hybrid vehicles. Proceedings of the American Control Conference, Chicago, Illinois, 524-528. https://doi.org/10.1109/ACC.2000.878955 |
[46] | Lin CC, Peng H, Grizzle JW (2004) A stochastic control strategy for hybrid electric vehicles. Proceedings of the American Control Conference, Boston, Massachusetts, IEEE Xplore, 4710-4715. https://doi.org/10.23919/ACC.2004.1384056. |
[47] | Panday A, Bansal HO (2016) Energy management strategy for hybrid electric vehicles using genetic algorithm. J Renewable Sustainable Energy, 8. https://doi.org/10.1063/1.4938552 |
[48] | Lorf CF (2014) Optimum battery capacity for electric vehicles with particular focus on battery degradation. Imperial College London, 10-105. https://doi.org/10.25560/13800 |
[49] |
Mokrani Z, Rekioua D, Rekioua T (2014) Modeling, control and power management of hybrid photovoltaic fuel cells with battery bank supplying electric vehicle. Int J Hydrogen Energy 39: 15178-15187. https://doi.org/10.1016/j.ijhydene.2014.03.215 doi: 10.1016/j.ijhydene.2014.03.215
![]() |
[50] |
Li Q, Yang H, Han Y, et al. (2016) A state machine strategy based on droop control for an energy management system of pemfc-battery-supercapacitor hybrid tramway. Int J Hydrogen Energy 41: 16148-16159. https://doi.org/10.1016/j.ijhydene.2016.04.254 doi: 10.1016/j.ijhydene.2016.04.254
![]() |
[51] | Chin HH, Jafari AA (2011) A selection algorithm for power controller unit of hybrid vehicles. International IEEE Conference on Intelligent Transportation Systems, ITSC, Washington, DC, USA, IEEE, 324-328. https://doi.org/10.1109/ITSC.2011.6082910 |
[52] |
Zou Y, Liu T, Liu D, et al. (2016) Reinforcement learning-based real-time energy management for a hybrid tracked vehicle. Appl Energy 171: 372-382. https://doi.org/10.1016/j.apenergy.2016.03.082 doi: 10.1016/j.apenergy.2016.03.082
![]() |
[53] |
Venditti M (2016) Analysis of the performance of different machine learning techniques for the definition of rule-based control strategies in a parallel HEV. Energy Procedia 101: 685-692. https://doi.org/10.1016/j.egypro.2016.11.087 doi: 10.1016/j.egypro.2016.11.087
![]() |
[54] |
Murphey YL, Park J, Chen Z, et al. (2012) Intelligent hybrid vehicle power control Part I: Machine learning of optimal vehicle power. IEEE Trans Veh Technol 61: 3519-3530. https://doi.org/10.1109/TVT.2012.2206064 doi: 10.1109/TVT.2012.2206064
![]() |
[55] |
Marina Martinez C, Heucke M, Wang FY, et al. (2018) Driving style recognition for intelligent vehicle control and advanced driver assistance: A survey. IEEE Trans Intell Transp Syst 19: 666-676. https://doi.org/10.1109/TITS.2017.2706978 doi: 10.1109/TITS.2017.2706978
![]() |
[56] |
Li W, Xu G, Xu Y (2012) Online learning control for hybrid electric vehicle. Chinese J Mech Eng (English Ed) 25: 98-106. https://doi.org/10.3901/CJME.2012.01.098 doi: 10.3901/CJME.2012.01.098
![]() |
[57] |
Hu Y, Li W, Xu H, et al. (2015) An online learning control strategy for hybrid electric vehicle based on fuzzy q-learning. Energies 8: 11167-11186. https://doi.org/10.3390/en81011167 doi: 10.3390/en81011167
![]() |
[58] |
Zhang W, Li J, Xu L, et al. (2017) Optimization for a fuel cell/battery/capacity tram with equivalent consumption minimization strategy. Energy Convers Manag 134: 59-69. https://doi.org/10.1016/j.enconman.2016.11.007 doi: 10.1016/j.enconman.2016.11.007
![]() |
[59] | Qi X, Wu G, Boriboonsomsin K, et al. (2016) Data-Driven reinforcement learning-based real-time energy management system for plug-in hybrid electric vehicles. Transp Res Rec, 1-8. https://doi.org/10.3141%2F2572-01 |
[60] |
Li Y, He H, Peng J, et al. (2017) Power management for a plug-in hybrid electric vehicle based on reinforcement learning with continuous state and action spaces. Energy Procedia 142: 2270-2275. https://doi.org/10.1016/j.egypro.2017.12.629 doi: 10.1016/j.egypro.2017.12.629
![]() |
[61] | Lin X, Bogdan P, Chang N, et al. (2015) Machine learning-based energy management in a hybrid electric vehicle to minimize total operating cost. IEEE/ACM International Conference on Computer-Aided Design, ICCAD, IEEE, 627-634. https://doi.org/10.1109/ICCAD.2015.7372628 |
[62] |
Gao J, Li M, Hu Y, et al. (2019) Challenges and Developments of automotive fuel cell hybrid power system and control. Sci China Inf Sci 62: 2-26. https://doi.org/10.1007/s11432-018-9690-y doi: 10.1007/s11432-018-9690-y
![]() |
[63] | Yue M (2019) Contribution of developing a prognostics-based energy management strategy for fuel cell hybrid system—application to a fuel cell/battery hybrid electric vehicle. Université Bourgogne Franche-Comté. Available from: https://tel.archives-ouvertes.fr/tel-02744268. |
[64] |
Sinoquet D, Rousseau G, Milhau Y (2011) Design optimization and optimal control for hybrid vehicles. Optim Eng 12: 199-213. https://doi.org/10.1007/s11081-009-9100-8 doi: 10.1007/s11081-009-9100-8
![]() |
[65] | Paganelli G, Delprat S, Guerra TM, et al. (2002) Equivalent consumption minimization strategy for parallel hybrid powertrains. Vehicular Technology Conference, Dresden, Germany, IEEE, 2076-2081. https://doi.org/10.1109/VTC.2002.1002989 |
[66] |
Zheng Q, Yuan H, Wu J, et al. (2018) Equivalent consumption minimization strategy based on dynamic programming for plug-in hybrid electric vehicle. IFAC-PapersOnLine 51: 612-617. https://doi.org/10.1016/j.ifacol.2018.10.146 doi: 10.1016/j.ifacol.2018.10.146
![]() |
[67] |
Rodatz P, Paganelli G, Sciarretta A, et al. (2005) Optimal power management of an experimental fuel cell/supercapacitor- powered hybrid vehicle. Control Eng Pract 13: 41-53. https://doi.org/10.1016/j.conengprac.2003.12.016 doi: 10.1016/j.conengprac.2003.12.016
![]() |
[68] | Banvait H, Member S, Hu J (2013) Energy management control of plug-in hybrid electric vehicle using hybrid dynamical systems set of discrete inputs. IEEE Trans Intell Transp Syst XX: 1-13. https://doi.org/10.1109/IEVC.2012.6183215 |
[69] |
Han J, Charpentier JF, Tang T (2014) An Energy management system of a fuel cell/battery hybrid boat. Energies 7: 2799-2820. https://doi.org/10.3390/en7052799 doi: 10.3390/en7052799
![]() |
[70] |
Xu L, Mueller CD, Li J, et al. (2015) Multi-objective component sizing based on optimal energy management strategy of fuel cell electric vehicles. Appl Energy 157: 664-674. https://doi.org/10.1016/j.apenergy.2015.02.017 doi: 10.1016/j.apenergy.2015.02.017
![]() |
[71] |
Johannesson L, Åsbogård M, Egardt B (2007) Assessing the potential of predictive control for hybrid vehicle powertrains using stochastic dynamic programming. IEEE Trans Intell Transp Syst 8: 71-83. https://doi.org/10.1109/TITS.2006.884887 doi: 10.1109/TITS.2006.884887
![]() |
[72] | Chen Z, Mi CC (2009) An adaptive online energy management controller for power-split HEV based on dynamic programming and fuzzy logic. 5th IEEE Vehicle Power and Propulsion Conference, VPPC, Michigan, IEEE, 335-339. https://doi.org/10.1109/VPPC.2009.5289831 |
[73] | Williamson SS (2013) Energy management strategies for electric and plug-in hybrid electric vehicles, 1 Eds., London: Springer, 50-150. https://doi.org/10.1007/978-1-4614-7711-2 |
[74] |
Dextreit C, Kolmanovsky IV (2014) Game theory controller for hybrid electric vehicles. IEEE Trans Control Syst Technol 22: 652-663. https://doi.org/10.1109/TCST.2013.2254597 doi: 10.1109/TCST.2013.2254597
![]() |
[75] | Smithson Bell JK (2016) Design and control of a hydrogen fuel cell vehicle. University of California IRVINE. Available from: https://escholarship.org/uc/item/5jg115q0. |
[76] | Gielniak MJ, Shen ZJ (2004) Power management strategy based on game theory for fuel cell hybrid electric vehicles. IEEE Vehicular Technology Conference, Los Angeles, CA, USA., IEEE, 4422-4426. https://doi.org/10.1109/VETECF.2004.1404915 |
[77] | Kennedy J, Eberhart R (1995) Particle swarm optimization. International Conference on Neural Networks, Perth, Australia, 1942-1948. https://doi.org/10.1109/ICNN.1995.488968 |
[78] | Wang Z, Huang B, Li W, et al. (2006) Particle swarm optimization for operational parameters of series hybrid electric vehicle. IEEE International Conference on Robotics and Biomimetics, ROBIO, Kunming, China, IEEE, 682-688. https://doi.org/10.1109/ROBIO.2006.340289 |
[79] | Lin X, Banvait H, Anwar S, et al. (2010) Optimal energy management for a plug-in hybrid electric vehicle: Real-time controller. American Control Conference, ACC, Baltimore, MD, USA, 5037-5042. https://doi.org/10.1109/ACC.2009.5160242 |
[80] | Hegazy O, Van Mierlo J (2010) Particle swarm optimization for optimal powertrain component sizing and design of fuel cell hybrid electric vehicle. International Conference on Optimisation of Electrical and Electronic Equipment, OPTIM, 601-609. https://doi.org/10.1109/OPTIM.2010.5510447 |
[81] | Desai C, Williamson SS (2010) Particle swarm optimization for efficient selection of hybrid electric vehicle design parameters. IEEE Energy Conversion Congress and Exposition, ECCE, IEEE, 1623-1628. https://doi.org/10.1109/ECCE.2010.5618098 |
[82] | Piccolo A, Ippolito L, Zo Galdi V, et al. (2001) Optimisation of energy flow management in hybrid electric vehicles via genetic algorithms. IEEE/ASME International Conference on Advanced Intelligent Mechatronics, AIM, Como, Italy, 434-439. https://doi.org/10.1109/AIM.2001.936493 |
[83] |
Chen Z, Mi CC, Xiong R, et al. (2014) Energy management of a power-split plug-in hybrid electric vehicle based on genetic algorithm and quadratic programming. J Power Sources 248: 416-426. https://doi.org/10.1016/j.jpowsour.2013.09.085 doi: 10.1016/j.jpowsour.2013.09.085
![]() |
[84] | Desai C, Williamson SS (2009) Optimal design of a parallel hybrid electric vehicle using multi-objective genetic algorithms. IEEE Vehicle Power and Propulsion Conference, VPPC, IEEE, 871-876. https://doi.org/10.1109/VPPC.2009.5289754 |
[85] |
Kirkpatrick S, Gelatt CD, Vecchi MP (1983) Optimization by simulated annealing. Science 220: 671-680. https://doi.org/10.1126/science.220.4598.671 doi: 10.1126/science.220.4598.671
![]() |
[86] | Wang Z, Huang B, Xu Y, et al. (2007) Optimization of series hybrid electric vehicle operational parameters by simulated annealing algorithm. IEEE International Conference on Control and Automation, ICCA, Guangzhou, China, 1536-1541. https://doi.org/10.1109/ICCA.2007.4376618 |
[87] |
Hui S (2010) Multi-Objective optimization for hydraulic hybrid vehicle based on adaptive simulated annealing genetic algorithm. Eng Appl Artif Intell 23: 27-33. https://doi.org/10.1016/j.engappai.2009.09.005 doi: 10.1016/j.engappai.2009.09.005
![]() |
[88] | Sharma A (2015) Comparative study of researches published in the past decade on short term load forecasting. Int J Recent Technol Mech Electr Eng 2: 25-31. Available from: https://www.semanticscholar.org/paper/Comparative-Study-of-Researches-Published-in-the-on-Sharma/c96431c0ff9a111a340c70a2a7b60bb9456ee421. |
[89] |
Chen Z, Mi CC, Xia B, et al. (2014) Energy management of power-split plug-in hybrid electric vehicles based on simulated annealing and Pontryagin's minimum principle. J Power Sources 272: 160-168. https://doi.org/10.1016/j.jpowsour.2014.08.057 doi: 10.1016/j.jpowsour.2014.08.057
![]() |
[90] | Beck R, Bollig A, Abel D (2006) Comparison of two real-time predictive strategies for the optimal energy management of a hybrid electric vehicle. E-COSM—Rencontres Scientifiques de l'IFP, Rueil-Malmaison, France, IFP—E-COSM, 1-8. Available from: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.601.7319&rep=rep1&type=pdf. |
[91] |
Koot M, Kessels JTBA, Jager B de, et al. (2015) Energy management strategies for vehicular electric power systems. IEEE Trans Veh Technol 54: 771-782. https://doi.org/10.1109/TVT.2005.847211 doi: 10.1109/TVT.2005.847211
![]() |
[92] |
Egardt B, Murgovski N, Pourabdollah M, et al. (2014) Electromobility studies based on convex optimization. IEEE Control Syst Mag 34: 32-49. https://doi.org/10.1109/MCS.2013.2295709 doi: 10.1109/MCS.2013.2295709
![]() |
[93] |
Hu X, Murgovski N, Johannesson L, et al. (2013) Energy efficiency analysis of a series plug-in hybrid electric bus with different energy management strategies and battery sizes. Appl Energy 111: 1001-1009. https://doi.org/10.1016/j.apenergy.2013.06.056 doi: 10.1016/j.apenergy.2013.06.056
![]() |
[94] |
Zhang M, Yang Y, Mi CC (2012) Analytical approach for the power management of blended-mode plug-in hybrid electric vehicles. IEEE Trans Veh Technol 61: 1554-1566. https://doi.org/10.1109/TVT.2012.2187318 doi: 10.1109/TVT.2012.2187318
![]() |
[95] | Hu X, Martinez CM, Egardt B, et al. (2015) Multi-objective optimal sizing and control of fuel cell systems for hybrid vehicle applications. European Control Conference, ECC, Linz, Austria, EUCA, 2559-2564. https://doi.org/10.1109/ECC.2015.7330923 |
[96] |
Hu X, Johannesson L, Murgovski N, et al. (2015) Longevity-conscious dimensioning and power management of the hybrid energy storage system in a fuel cell hybrid electric bus. Appl Energy 137: 913-924. https://doi.org/10.1016/j.apenergy.2014.05.013 doi: 10.1016/j.apenergy.2014.05.013
![]() |
[97] |
Lin CC, Peng H, Grizzle JW, et al. (2003) Power management strategy for a parallel hybrid electric truck. IEEE Trans Control Syst Technol 11: 839-849. https://doi.org/10.1109/TCST.2003.815606 doi: 10.1109/TCST.2003.815606
![]() |
[98] | Gong Q, Li Y, Peng ZR (2007) Trip based power management of plug-in hybrid electric vehicle with two-scale dynamic programming. IEEE Vehicle Power and Propulsion Conference, Arlington, Texas, IEEE, 12-19. https://doi.org/10.1109/VPPC.2007.4544089 |
[99] | Sundström O, Stefanopoulou A (2006) Optimal power split in fuel cell hHybrid electric vehicle with different battery sizes, drive cycles, and objectives. IEEE International Conference on Control Applications, Munich, 1681-1688. https://doi.org/10.1109/CCA.2006.286107 |
[100] |
Santucci A, Sorniotti A, Lekakou C (2014) Power split strategies for hybrid energy storage systems for vehicular applications. J Power Sources 258: 395-407. https://doi.org/10.1016/j.jpowsour.2014.01.118 doi: 10.1016/j.jpowsour.2014.01.118
![]() |
[101] |
Panday A, Bansal HO (2014) A review of optimal energy management strategies for hybrid electric vehicle. Int J Veh Technol 2014: 1-18. https://doi.org/10.1007/s12239-015-0092-4 doi: 10.1007/s12239-015-0092-4
![]() |
[102] |
Lee SH, Kim TY (2015) Combustion and emission characteristics of wood pyrolysis oil-butanol blended fuels in a di diesel engine. Int J Automot Technol 16: 903-912. https://doi.org/10.1007/s12239-015-0092-4 doi: 10.1007/s12239-015-0092-4
![]() |
[103] | Sebastien D, Marie GT, Gin P, et al. (2001) Control strategy optimization for an hybrid parallel powertrain. Proceedings of the American Control Conference, Arlington, VA, 1315-1320. https://doi.org/10.1109/ACC.2001.945905 |
[104] | Serrao L, Rizzoni G (2008) Optimal control of power split for a hybrid electric refuse vehicle. Proceedings of the American Control Conference, Seattle, Washington, 4498-4503. https://doi.org/10.1109/ACC.2008.4587204 |
[105] | Bernard J, Delprat S, Buechi F, et al. (2006) Global optimisation in the power management of a fuel cell hybrid vehicle (FCHV). IEEE Veh Power Propuls Conf VPPC. 1-6. https://doi.org/10.1109/VPPC.2006.364289 |
[106] |
Hemi H, Ghouili J, Cheriti A (2015) Combination of Markov chain and optimal control solved by Pontryagin's minimum principle for a fuel cell/supercapacitor vehicle. Energy Convers Manag 91: 387-393. https://doi.org/10.1016/j.enconman.2014.12.035 doi: 10.1016/j.enconman.2014.12.035
![]() |
[107] |
Delprat S, Lauber J, Guerra TM, et al. (2004) Control of a parallel hybrid powertrain: Optimal control. IEEE Trans Veh Technol 53: 872-881. https://doi.org/10.1109/TVT.2004.827161 doi: 10.1109/TVT.2004.827161
![]() |
[108] | Pham TH, Kessels JTBA, Van Den Bosch PPJ, et al. (2013) On-line energy and battery thermal management for hybrid electric heavy-duty truck. Proceedings of the American Control Conference, Washington, DC, USA, IEEE, 710-715. https://doi.org/10.1109/ACC.2013.6579919 |
[109] |
Kessels JTBA, Koot MWT, Bosch PPJ van den, et al. (2008) Online energy management for hybrid electric vehicles. IEEE Trans Veh Technol 57: 21-36. https://doi.org/10.1109/TVT.2008.919988 doi: 10.1109/TVT.2008.919988
![]() |
[110] | Yu H, Kuang M, McGee R (2014) Trip-oriented energy management control strategy for plug-in hybrid electric vehicles. IEEE Transactions on Control Systems Technology, Orlando, FL, USA, IEEE, 1323-1336. https://doi.org/10.1109/TCST.2013.2278684 |
[111] | Schori M, Boehme TJ, Jeinsch T, et al. (2015) A robust predictive energy management for plug-in hybrid vehicles based on hybrid optimal control theory. Proceedings of the American Control Conference, American Automatic Control Council, 2278-2283. https://doi.org/10.1109/ACC.2015.7171072 |
[112] |
Hou C, Ouyang M, Xu L, et al. (2014) Approximate Pontryagin's minimum principle applied to the energy management of plug-in hybrid electric vehicles. Appl Energy 115: 174-189. https://doi.org/10.1016/j.apenergy.2013.11.002 doi: 10.1016/j.apenergy.2013.11.002
![]() |
[113] |
Weyers C, Bocklisch T (2018) Simulation-Based investigation of energy management concepts for fuel cell—battery—hybrid energy systems in mobile mobile applications. Energy Procedia 155: 295-308. https://doi.org/10.1016/j.egypro.2018.11.048 doi: 10.1016/j.egypro.2018.11.048
![]() |
[114] |
Robledo CB, Oldenbroek V, Abbruzzese F, et al. (2018) Integrating a hydrogen fuel cell electric vehicle with vehicle-to-grid technology, photovoltaic power and a residential building. Appl Energy 215: 615-629. https://doi.org/10.1016/j.apenergy.2018.02.038 doi: 10.1016/j.apenergy.2018.02.038
![]() |
[115] |
Elbert P, Nuesch T, Ritter A, et al. (2014) Engine On/Off control for the energy management of a serial hybrid electric bus via convex optimization. IEEE Trans Veh Technol 63: 3549-3559. https://doi.org/10.1109/TVT.2014.2304137 doi: 10.1109/TVT.2014.2304137
![]() |
[116] | Opila DF, Wang X, McGee R, et al. (2014) Real-world robustness for hybrid vehicle optimal energy management strategies incorporating drivability metrics. J Dyn Syst Meas Control Trans ASME 136. https://doi.org/10.1115/1.4027680 |
[117] | Fister I, Yang XS, Brest J, et al. (2013) A brief review of nature-inspired algorithms for optimization. Elektroteh Vestnik/Electrotechnical Rev 80: 116-122. Available from: https://www.researchgate.net/publication/249645112_A_Brief_Review_of_Nature-Inspired_Algorithms_for_Optimization. |
[118] |
Wu W, Chuang B-N, Hwang J-J, et al. (2019) Techno-Economic evaluation of a hybrid fuel cell vehicle with on-board meoh-to-h2 processor. Appl Energy 238: 401-412. https://doi.org/10.1016/j.apenergy.2019.01.089 doi: 10.1016/j.apenergy.2019.01.089
![]() |
[119] |
Corral-Vega PJ, García-Triviño P, Fernández-Ramírez LM (2019) Design, modelling, control and techno-economic evaluation of a fuel cell/supercapacitors powered container crane. Energy 186: 1-13. https://doi.org/10.1016/j.energy.2019.115863 doi: 10.1016/j.energy.2019.115863
![]() |
[120] |
Hosseini SE, Butler B (2020) An overview of development and challenges in hydrogen powered vehicles. Int J Green Energy 17: 13-37. https://doi.org/10.1080/15435075.2019.1685999 doi: 10.1080/15435075.2019.1685999
![]() |
[121] | Waschl H, Kolmanovsky I, Willems F (2019) Control strategies for advanced driver assitance systems and autonomous driving functions, 476 Eds., New York: Springer Nature, 50-150. https://doi.org/10.1007/978-3-319-91569-2 |
[122] | Waschl H, Kolmanovsky I, Steinbuch M, et al. (2014) Optimization and optimal control in automotive systems, 455 Eds., New York: Springer, 41-100. Available from: http://www.springer.com/series/642. |
[123] | Amini MR, Gong X, Feng Y, et al. (2019) Sequential optimization of speed, thermal load, and power split in connected HEVs. American Control Conference, 4614-4620. https://doi.org/10.23919/ACC.2019.8815158 |
[124] |
van Reeven V, Hofman T (2019) Multi-Level energy management for hybrid electric vehicles—Part I. Vehicles 1: 3-40. https://doi.org/10.3390/vehicles1010002 doi: 10.3390/vehicles1010002
![]() |
[125] |
Zhang L, Liang W, Zheng X (2018) Eco-Driving for public transit in cyber-physical systems using v2i communication. Int J Intell Transp Syst Res 16: 79-89. https://doi.org/10.1007/s13177-017-0139-1 doi: 10.1007/s13177-017-0139-1
![]() |
[126] |
Xie S, Hu X, Liu T, et al. (2019) Predictive vehicle-following power management for plug-in hybrid electric vehicles. Energy 166: 701-714. https://doi.org/10.1016/j.energy.2018.10.129 doi: 10.1016/j.energy.2018.10.129
![]() |
[127] |
Ma G, Ghasemi M, Song X (2018) Integrated powertrain energy management and vehicle coordination for multiple connected hybrid electric vehicles. IEEE Trans Veh Technol 67: 2893-2899. https://doi.org/10.1109/TVT.2017.2780268 doi: 10.1109/TVT.2017.2780268
![]() |
1. | Hongmei Zhang, Mengchen Zhang, Fawang Liu, Ming Shen, Review of the Fractional Black-Scholes Equations and Their Solution Techniques, 2024, 8, 2504-3110, 101, 10.3390/fractalfract8020101 | |
2. | Xindong Zhang, Yuelong Feng, Ziyang Luo, Juan Liu, A spatial sixth-order numerical scheme for solving fractional partial differential equation, 2025, 159, 08939659, 109265, 10.1016/j.aml.2024.109265 | |
3. | Xiurong Dai, Malik Zaka Ullah, An Efficient Higher-Order Numerical Scheme for Solving Fractional Black-Scholes PDE Using Analytical Weights, 2024, 48, 2731-8095, 423, 10.1007/s40995-024-01588-x |
Overall (n =361) | Duration of viral shedding ≤ 21d (n =111) |
Duration of viral shedding > 21d (n =250) |
P-value |
||
Demographics and clinical characteristics | |||||
Sex | |||||
Male | 139 (38.5) | 47 (42.3) | 92 (36.8) | 0.349 | |
Female | 222 (61.5) | 64 (57.7) | 158 (63.2) | ||
Age, years | 50.00 [40.00, 65.00] | 49.00 [34.50, 62.00] | 50.00 [41.00, 66.00] | 0.101 | |
With any comorbidity | |||||
No | 257 (71.2) | 81 (73.0) | 176 (70.4) | 0.706 | |
Yes | 104 (28.8) | 30 (27.0) | 74 (29.6) | ||
Hypertension | |||||
No | 284 (78.7) | 90 (81.1) | 194 (77.6) | 0.489 | |
Yes | 77 (21.3) | 21 (18.9) | 56 (22.4) | ||
Diabetes | |||||
No | 330 (91.4) | 105 (94.6) | 225 (90.0) | 0.221 | |
Yes | 31 (8.6) | 6 (5.4) | 25 (10.0) | ||
Heart disease | |||||
No | 349 (96.7) | 106 (95.5) | 243 (97.2) | 0.525 | |
Yes | 12 (3.3) | 5 (4.5) | 7 (2.8) | ||
COPD | |||||
No | 361 (100.0) | 111 (100.0) | 250 (100.0) | ||
Yes | 0(0.0) | 0(0.0) | 0(0.0) | ||
Carcinoma history | |||||
No | 353 (97.8) | 111 (100.0) | 242 (96.8) | 0.113 | |
Yes | 8 (2.2) | 0 (0.0) | 8 (3.2) | ||
Asthma | |||||
No | 356 (98.6) | 111 (100.0) | 245 (98.0) | 0.329 | |
Yes | 5 (1.4) | 0 (0.0) | 5 (2.0) | ||
Autoimmune diseases | |||||
No | 357 (98.9) | 110 (99.1) | 247 (98.8) | 1.000 | |
Yes | 4 (1.1) | 1 (0.9) | 3 (1.2) | ||
Vaccination Status | |||||
Unvaccinated | 121 (33.5) | 29 (26.1) | 92 (36.8) | 0.046 | |
Partially vaccinated | 64 (17.7) | 17 (15.3) | 47 (18.8) | ||
Fully vaccinated | 176 (48.8) | 65 (58.6) | 111 (44.4) | ||
Time from illness onset to hospitalization (median [IQR]) | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 0.192 | |
Symptoms | |||||
Fever | |||||
No | 247 (68.4) | 77 (69.4) | 170 (68.0) | 0.902 | |
Yes | 114 (31.6) | 34 (30.6) | 80 (32.0) | ||
Cough | |||||
No | 179 (49.6) | 56 (50.5) | 123 (49.2) | 0.909 | |
Yes | 182 (50.4) | 55 (49.5) | 127 (50.8) | ||
Sputum production | |||||
No | 294 (81.4) | 90 (81.1) | 204 (81.6) | 0.885 | |
Yes | 67 (18.6) | 21 (18.9) | 46 (18.4) | ||
Shortness of breath | |||||
No | 349 (96.7) | 109 (98.2) | 240 (96.0) | 0.357 | |
Yes | 12 (3.3) | 2 (1.8) | 10 (4.0) | ||
Nausea or vomiting | |||||
No | 355 (98.3) | 110 (99.1) | 245 (98.0) | 0.671 | |
Yes | 6 (1.7) | 1 (0.9) | 5 (2.0) | ||
Abdominal pain or diarrhea | |||||
No | 340 (94.2) | 103 (92.8) | 237 (94.8) | 0.470 | |
Yes | 21 (5.8) | 8 (7.2) | 13 (5.2) | ||
Loss of smell or taste | |||||
No | 347 (96.1) | 105 (94.6) | 242 (96.8) | 0.377 | |
Yes | 14 (3.9) | 6 (5.4) | 8 (3.2) | ||
Myalgia | |||||
No | 351 (97.2) | 108 (97.3) | 243 (97.2) | 1.000 | |
Yes | 10 (2.8) | 3 (2.7) | 7 (2.8) | ||
Stuffy nose or runny nose | |||||
No | 311 (86.1) | 92 (82.9) | 219 (87.6) | 0.249 | |
Yes | 50 (13.9) | 19 (17.1) | 31 (12.4) | ||
Headache or dizziness | |||||
No | 334 (92.5) | 106 (95.5) | 228 (91.2) | 0.195 | |
Yes | 27 (7.5) | 5 (4.5) | 22 (8.8) | ||
Fatigue | |||||
No | 291 (80.6) | 93 (83.8) | 198 (79.2) | 0.387 | |
Yes | 70 (19.4) | 18 (16.2) | 52 (20.8) | ||
Pharyngeal discomfort | |||||
No | 280 (77.6) | 91 (82.0) | 189 (75.6) | 0.219 | |
Yes | 81 (22.4) | 20 (18.0) | 61 (24.4) | ||
Blood laboratory findings | |||||
C-reactive protein, mg/L | 5.41 [2.04, 14.31] | 5.77 [1.31, 17.01] | 5.21 [2.52, 13.53] | 0.868 | |
Procalcitonin, ng/mL | 0.04 [0.02, 0.06] | 0.04 [0.02, 0.07] | 0.04 [0.03, 0.06] | 0.583 | |
Interleukin-6, pg/mL | 10.06 [2.81, 21.13] | 10.69 [4.54, 21.02] | 9.80 [2.33, 20.95] | 0.453 | |
White blood cell count, × 109/L | 4.82 [3.91, 5.98] | 4.79 [3.84, 6.30] | 4.85 [3.94, 5.90] | 0.918 | |
Neutrophil count, × 109/L | 3.00 [2.19, 4.02] | 2.94 [2.06, 4.19] | 3.04 [2.28, 3.86] | 0.679 | |
Lymphocyte count, × 109/L | 1.15 [0.88, 1.54] | 1.23 [1.00, 1.60] | 1.11 [0.86, 1.47] | 0.017 | |
Hemoglobin, g/dL | 13.20 [12.30, 14.60] | 13.40 [12.35, 14.85] | 13.10 [12.30, 14.50] | 0.352 | |
Platelet count, × 109/L | 157.00 [121.00,192.00] | 165.00 [130.00,200.50] | 152.00 [118.25,189.00] | 0.102 | |
Albumin, g/L | 42.80 [40.40, 45.30] | 43.10 [40.60, 45.45] | 42.70 [40.20, 45.20] | 0.261 | |
Total bilirubin, umol/L | 9.70 [7.60, 12.30] | 9.90 [7.75, 12.10] | 9.50 [7.53, 12.57] | 0.981 | |
AST, U/L | 17.00 [13.90, 23.10] | 16.10 [13.65, 23.30] | 17.30 [14.35, 23.10] | 0.189 | |
ALT, U/L | 18.10 [12.20, 28.50] | 19.50 [12.00, 30.80] | 17.40 [12.35, 28.10] | 0.702 | |
Urea nitrogen, mmol/L | 4.36 [3.59, 5.24] | 4.33 [3.62, 5.22] | 4.40 [3.59, 5.27] | 0.615 | |
Creatinine, μmol/L | 60.80 [51.90, 74.90] | 63.50 [54.80, 76.50] | 59.15 [51.12, 74.12] | 0.045 | |
eGFR, mL/min | 111.95 [105.75,117.14] | 111.95 [104.68,119.67] | 111.95 [106.93,115.50] | 0.944 | |
Creatine kinase, U/L | 71.00 [50.00,112.00] | 71.00 [51.50,104.00] | 69.50 [50.00,115.75] | 0.698 | |
CK-MB, ng/mL | 0.50 [0.30, 0.80] | 0.50 [0.30, 0.85] | 0.50 [0.30, 0.80] | 0.990 | |
Myoglobin, ng/mL | 34.05 [23.60, 49.50] | 34.05 [25.80, 49.90] | 34.05 [22.22, 48.98] | 0.464 | |
Troponin I, pg/mL | 3.00 [1.00, 6.20] | 3.00 [0.80, 5.45] | 3.00 [1.10, 6.40] | 0.580 | |
LDH, U/L | 237.00 [202.00,280.00] | 234.00 [200.00,269.50] | 238.50 [206.00,284.00] | 0.251 | |
D-dimer, mg/L | 0.39 [0.25, 0.60] | 0.40 [0.25, 0.67] | 0.38 [0.25, 0.60] | 0.957 | |
FDPs, ug/mL | 2.70 [1.70, 5.10] | 3.10 [1.55, 5.40] | 2.70 [1.70, 4.10] | 0.242 | |
SARS-COV-2 IgM (S/CO) | 0.19 [0.06, 0.75] | 0.34 [0.11, 1.36] | 0.15 [0.05, 0.60] | < 0.001 | |
SARS-COV-2 IgG (S/CO) | 1.13 [0.15, 7.61] | 3.31 [0.38, 25.44] | 0.67 [0.11, 3.95] | < 0.001 | |
Abbreviations: AST, Aspartate Transaminase; ALT, Alanine Aminotransferase; eGFR, estimated Giomerular Filtration Rate; CK-MB, Creatine Kinase Isoenzyme; LDH, Lactic Dehydrogenase; FDPs, Fibrinogen Degrdtion Products; SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
Vaccination status | |||||
Type of antibody | Overall | fully vaccinated | partially vaccinated | unvaccinated | |
SARS-COV-2 IgM (median [IQR]) |
0.19 [0.06, 0.75] | 0.30 [0.10, 1.17] | 0.36 [0.08, 0.96] | 0.05 [0.03, 0.31] | |
SARS-COV-2 IgG (median [IQR]) | 1.13 [0.15, 7.61] | 4.77 [2.24, 24.41] | 0.43 [0.15, 1.62] | 0.10 [0.05, 0.25] | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
Effects | Parameter | Estimate | Std Err | P value |
Log(SARS-COV-2) IgM (S/CO)) | Intercept | -1.405 | 0.082 | < 0.001 |
days | 0.193 | 0.017 | < 0.001 | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M |
Parameter | Estimate | exp(coef) | Std Err | P value |
Sex | 0.205 | 1.228 | 0.1093 | 0.0608 |
Parameter | Estimate | Std Err | P value |
Sex | 0.274 | 0.005 | 0.056 |
Assoct | 0.430 | 0.039 | < 0.001 |
Overall (n =361) | Duration of viral shedding ≤ 21d (n =111) |
Duration of viral shedding > 21d (n =250) |
P-value |
||
Demographics and clinical characteristics | |||||
Sex | |||||
Male | 139 (38.5) | 47 (42.3) | 92 (36.8) | 0.349 | |
Female | 222 (61.5) | 64 (57.7) | 158 (63.2) | ||
Age, years | 50.00 [40.00, 65.00] | 49.00 [34.50, 62.00] | 50.00 [41.00, 66.00] | 0.101 | |
With any comorbidity | |||||
No | 257 (71.2) | 81 (73.0) | 176 (70.4) | 0.706 | |
Yes | 104 (28.8) | 30 (27.0) | 74 (29.6) | ||
Hypertension | |||||
No | 284 (78.7) | 90 (81.1) | 194 (77.6) | 0.489 | |
Yes | 77 (21.3) | 21 (18.9) | 56 (22.4) | ||
Diabetes | |||||
No | 330 (91.4) | 105 (94.6) | 225 (90.0) | 0.221 | |
Yes | 31 (8.6) | 6 (5.4) | 25 (10.0) | ||
Heart disease | |||||
No | 349 (96.7) | 106 (95.5) | 243 (97.2) | 0.525 | |
Yes | 12 (3.3) | 5 (4.5) | 7 (2.8) | ||
COPD | |||||
No | 361 (100.0) | 111 (100.0) | 250 (100.0) | ||
Yes | 0(0.0) | 0(0.0) | 0(0.0) | ||
Carcinoma history | |||||
No | 353 (97.8) | 111 (100.0) | 242 (96.8) | 0.113 | |
Yes | 8 (2.2) | 0 (0.0) | 8 (3.2) | ||
Asthma | |||||
No | 356 (98.6) | 111 (100.0) | 245 (98.0) | 0.329 | |
Yes | 5 (1.4) | 0 (0.0) | 5 (2.0) | ||
Autoimmune diseases | |||||
No | 357 (98.9) | 110 (99.1) | 247 (98.8) | 1.000 | |
Yes | 4 (1.1) | 1 (0.9) | 3 (1.2) | ||
Vaccination Status | |||||
Unvaccinated | 121 (33.5) | 29 (26.1) | 92 (36.8) | 0.046 | |
Partially vaccinated | 64 (17.7) | 17 (15.3) | 47 (18.8) | ||
Fully vaccinated | 176 (48.8) | 65 (58.6) | 111 (44.4) | ||
Time from illness onset to hospitalization (median [IQR]) | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | 0.192 | |
Symptoms | |||||
Fever | |||||
No | 247 (68.4) | 77 (69.4) | 170 (68.0) | 0.902 | |
Yes | 114 (31.6) | 34 (30.6) | 80 (32.0) | ||
Cough | |||||
No | 179 (49.6) | 56 (50.5) | 123 (49.2) | 0.909 | |
Yes | 182 (50.4) | 55 (49.5) | 127 (50.8) | ||
Sputum production | |||||
No | 294 (81.4) | 90 (81.1) | 204 (81.6) | 0.885 | |
Yes | 67 (18.6) | 21 (18.9) | 46 (18.4) | ||
Shortness of breath | |||||
No | 349 (96.7) | 109 (98.2) | 240 (96.0) | 0.357 | |
Yes | 12 (3.3) | 2 (1.8) | 10 (4.0) | ||
Nausea or vomiting | |||||
No | 355 (98.3) | 110 (99.1) | 245 (98.0) | 0.671 | |
Yes | 6 (1.7) | 1 (0.9) | 5 (2.0) | ||
Abdominal pain or diarrhea | |||||
No | 340 (94.2) | 103 (92.8) | 237 (94.8) | 0.470 | |
Yes | 21 (5.8) | 8 (7.2) | 13 (5.2) | ||
Loss of smell or taste | |||||
No | 347 (96.1) | 105 (94.6) | 242 (96.8) | 0.377 | |
Yes | 14 (3.9) | 6 (5.4) | 8 (3.2) | ||
Myalgia | |||||
No | 351 (97.2) | 108 (97.3) | 243 (97.2) | 1.000 | |
Yes | 10 (2.8) | 3 (2.7) | 7 (2.8) | ||
Stuffy nose or runny nose | |||||
No | 311 (86.1) | 92 (82.9) | 219 (87.6) | 0.249 | |
Yes | 50 (13.9) | 19 (17.1) | 31 (12.4) | ||
Headache or dizziness | |||||
No | 334 (92.5) | 106 (95.5) | 228 (91.2) | 0.195 | |
Yes | 27 (7.5) | 5 (4.5) | 22 (8.8) | ||
Fatigue | |||||
No | 291 (80.6) | 93 (83.8) | 198 (79.2) | 0.387 | |
Yes | 70 (19.4) | 18 (16.2) | 52 (20.8) | ||
Pharyngeal discomfort | |||||
No | 280 (77.6) | 91 (82.0) | 189 (75.6) | 0.219 | |
Yes | 81 (22.4) | 20 (18.0) | 61 (24.4) | ||
Blood laboratory findings | |||||
C-reactive protein, mg/L | 5.41 [2.04, 14.31] | 5.77 [1.31, 17.01] | 5.21 [2.52, 13.53] | 0.868 | |
Procalcitonin, ng/mL | 0.04 [0.02, 0.06] | 0.04 [0.02, 0.07] | 0.04 [0.03, 0.06] | 0.583 | |
Interleukin-6, pg/mL | 10.06 [2.81, 21.13] | 10.69 [4.54, 21.02] | 9.80 [2.33, 20.95] | 0.453 | |
White blood cell count, × 109/L | 4.82 [3.91, 5.98] | 4.79 [3.84, 6.30] | 4.85 [3.94, 5.90] | 0.918 | |
Neutrophil count, × 109/L | 3.00 [2.19, 4.02] | 2.94 [2.06, 4.19] | 3.04 [2.28, 3.86] | 0.679 | |
Lymphocyte count, × 109/L | 1.15 [0.88, 1.54] | 1.23 [1.00, 1.60] | 1.11 [0.86, 1.47] | 0.017 | |
Hemoglobin, g/dL | 13.20 [12.30, 14.60] | 13.40 [12.35, 14.85] | 13.10 [12.30, 14.50] | 0.352 | |
Platelet count, × 109/L | 157.00 [121.00,192.00] | 165.00 [130.00,200.50] | 152.00 [118.25,189.00] | 0.102 | |
Albumin, g/L | 42.80 [40.40, 45.30] | 43.10 [40.60, 45.45] | 42.70 [40.20, 45.20] | 0.261 | |
Total bilirubin, umol/L | 9.70 [7.60, 12.30] | 9.90 [7.75, 12.10] | 9.50 [7.53, 12.57] | 0.981 | |
AST, U/L | 17.00 [13.90, 23.10] | 16.10 [13.65, 23.30] | 17.30 [14.35, 23.10] | 0.189 | |
ALT, U/L | 18.10 [12.20, 28.50] | 19.50 [12.00, 30.80] | 17.40 [12.35, 28.10] | 0.702 | |
Urea nitrogen, mmol/L | 4.36 [3.59, 5.24] | 4.33 [3.62, 5.22] | 4.40 [3.59, 5.27] | 0.615 | |
Creatinine, μmol/L | 60.80 [51.90, 74.90] | 63.50 [54.80, 76.50] | 59.15 [51.12, 74.12] | 0.045 | |
eGFR, mL/min | 111.95 [105.75,117.14] | 111.95 [104.68,119.67] | 111.95 [106.93,115.50] | 0.944 | |
Creatine kinase, U/L | 71.00 [50.00,112.00] | 71.00 [51.50,104.00] | 69.50 [50.00,115.75] | 0.698 | |
CK-MB, ng/mL | 0.50 [0.30, 0.80] | 0.50 [0.30, 0.85] | 0.50 [0.30, 0.80] | 0.990 | |
Myoglobin, ng/mL | 34.05 [23.60, 49.50] | 34.05 [25.80, 49.90] | 34.05 [22.22, 48.98] | 0.464 | |
Troponin I, pg/mL | 3.00 [1.00, 6.20] | 3.00 [0.80, 5.45] | 3.00 [1.10, 6.40] | 0.580 | |
LDH, U/L | 237.00 [202.00,280.00] | 234.00 [200.00,269.50] | 238.50 [206.00,284.00] | 0.251 | |
D-dimer, mg/L | 0.39 [0.25, 0.60] | 0.40 [0.25, 0.67] | 0.38 [0.25, 0.60] | 0.957 | |
FDPs, ug/mL | 2.70 [1.70, 5.10] | 3.10 [1.55, 5.40] | 2.70 [1.70, 4.10] | 0.242 | |
SARS-COV-2 IgM (S/CO) | 0.19 [0.06, 0.75] | 0.34 [0.11, 1.36] | 0.15 [0.05, 0.60] | < 0.001 | |
SARS-COV-2 IgG (S/CO) | 1.13 [0.15, 7.61] | 3.31 [0.38, 25.44] | 0.67 [0.11, 3.95] | < 0.001 | |
Abbreviations: AST, Aspartate Transaminase; ALT, Alanine Aminotransferase; eGFR, estimated Giomerular Filtration Rate; CK-MB, Creatine Kinase Isoenzyme; LDH, Lactic Dehydrogenase; FDPs, Fibrinogen Degrdtion Products; SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
Vaccination status | |||||
Type of antibody | Overall | fully vaccinated | partially vaccinated | unvaccinated | |
SARS-COV-2 IgM (median [IQR]) |
0.19 [0.06, 0.75] | 0.30 [0.10, 1.17] | 0.36 [0.08, 0.96] | 0.05 [0.03, 0.31] | |
SARS-COV-2 IgG (median [IQR]) | 1.13 [0.15, 7.61] | 4.77 [2.24, 24.41] | 0.43 [0.15, 1.62] | 0.10 [0.05, 0.25] | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M; SARS-COV-2 IgG, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G. |
Effects | Parameter | Estimate | Std Err | P value |
Log(SARS-COV-2) IgM (S/CO)) | Intercept | -1.405 | 0.082 | < 0.001 |
days | 0.193 | 0.017 | < 0.001 | |
Abbreviations: SARS-COV-2 IgM, Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin M |
Parameter | Estimate | exp(coef) | Std Err | P value |
Sex | 0.205 | 1.228 | 0.1093 | 0.0608 |
Parameter | Estimate | Std Err | P value |
Sex | 0.274 | 0.005 | 0.056 |
Assoct | 0.430 | 0.039 | < 0.001 |